These three clinical-stage biotechs could all double in value before year's end.
News & Analysis: Kiniksa Pharmaceuticals Ltd
A much-needed vote of confidence lifted an entire industry.
The company's lead drug candidate earned Breakthrough Therapy designation from American regulators.
Some investors think the market's been too hard on these drugmakers.